Key insights
- The author questions whether interest rate sensitivity fully explains the discounted valuation of General Mills (GIS) and other consumer staples. While higher rates may compress multiples, the author suggests GLP-1 drugs and private label competition could be eroding fundamentals, making historical valuations unsustainable even if rates normalize. The analysis highlights potential risks in assuming a simple reversion to the mean based solely on interest rate policy shifts.
When I pulled General Mills up on this screen it was trading 39% below its own 5 year median EV/EBIT and the explanation everyone reaches for is rates.
That's probably part of it. But I'm not sure it's the whole story.
GIS carries fixed rate long dated debt. Demand for its products doesn't move meaningfully with borrowing costs. The business generates consistent free cash flow regardless of where the 10 year sits.
So the rate sensitivity only explains the multiple, not the fundamentals.
This is exactly what I've been thinking about for a while now. Is GIS cheap because rates compressed the multiple and the discount reverses when policy shifts? Or is something else explaining the gap that doesn't go away when rates do?
The counterargument I keep running into is GLP-1s and private label competition. If consumers are eating less and trading down to store brands, the volume trends that supported GIS at higher multiples may not come back even if rates normalize.
I tried to add Treasury beta to the screen to quantify the rate sensitivity more precisely. The data wasn't available so I had to think through it qualitatively instead.
WTW and BF.B showed up with similar discounts to their own history. The pattern isn't unique to GIS. But the consumer staples rate sensitivity question is cleanest here so that's where I focused.
I don't own it. But a 39% discount to its own historical valuation on a business with fixed rate debt and non-discretionary demand is hard to walk away from without at least understanding why it's there.
Is this a rate overhang that clears when policy shifts? Or is the market already pricing the GLP-1 and private label story and deciding the old multiple was the anomaly?